Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib.
0 ratings in the last 12 months
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.